Celgene Primed For Growth Through 2017, Hugin Says At JPM
This article was originally published in The Pink Sheet Daily
Celgene CEO Bob Hugin gave investors a taste of what’s to come for the biotech as it prepares for multiple NDA filings this year and the influx of data on several new indications for its lead drugs.
You may also be interested in...
FDA clears Celgene’s Abraxane in lung cancer despite its lack of even a progression-free survival benefit. But the ease of approval is reassurance ahead of the release of melanoma results, with a PFS benefit, in November.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.